A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Triptorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PRIORITI
- Sponsors Ipsen
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 25 Oct 2019 Status changed from active, no longer recruiting to completed.
- 24 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.